PDZK1IP1, PDZK1 interacting protein 1, 10158

N. diseases: 46; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011334
Disease: Dental caries
Dental caries
0.010 GeneticVariation disease BEFREE Detection of Streptococcus mutans by PCR amplification of the spaP gene in teeth rendered caries free. 9699435 1998
CUI: C0025500
Disease: Mesothelioma
Mesothelioma
0.010 GeneticVariation disease LHGDN Transcriptome sequencing of malignant pleural mesothelioma tumors. 18303113 2008
CUI: C0333519
Disease: Caries (morphologic abnormality)
Caries (morphologic abnormality)
0.010 GeneticVariation disease BEFREE Detection of Streptococcus mutans by PCR amplification of the spaP gene in teeth rendered caries free. 9699435 1998
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.300 Biomarker group CTD_human Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. 17013881 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.300 Biomarker disease CTD_human Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. 17013881 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.080 Biomarker group BEFREE In a xenograft tumor model in which TGF-β was previously shown to elicit tumor-promoting effects, PDZK1IP1 gain of function decreased tumor size and increased survival rates. 30718277 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.030 Biomarker group BEFREE Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents. 10496535 1999
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.030 Biomarker group BEFREE The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. 28153862 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.030 Biomarker phenotype BEFREE p38α limits the contribution of MAP17 to cancer progression in breast tumors. 22266858 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.030 Biomarker phenotype BEFREE Immunohistochemical analysis of MAP17 during cancer progression shows, at least in prostate and ovarian carcinomas, that overexpression of the protein strongly correlates with tumoral progression (P < 0.0001). 17426052 2007
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.030 Biomarker phenotype BEFREE Furthermore, MAP17 is correlated with tumour progression. 30119639 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 Biomarker group BEFREE The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. 28153862 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 Biomarker group BEFREE EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties. 29616128 2018
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.030 Biomarker group BEFREE Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents. 10496535 1999
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.020 Biomarker disease BEFREE MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer. 25837675 2015
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.020 Biomarker disease BEFREE MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer. 25837675 2015
CUI: C0001430
Disease: Adenoma
Adenoma
0.010 Biomarker group BEFREE CIMP-H (>1 marker positive) was significantly more frequent in SPAP, SA, and SCa compared with MVSP (P<0.05); CIMP-H was present in 10% of sTAs but was found more frequently in lTA (44.4%; OR 7.2; P=0.007) and TCa (38.9%; OR 5.8; P=0.007). 17122504 2006
CUI: C0004238
Disease: Atrial Fibrillation
Atrial Fibrillation
0.010 Biomarker disease BEFREE Paroxysmal AF comparing to permanent AF and SR individuals had higher estimated SPAP (56 versus 48 versus 47 mmHg, <i>p</i> = 0.01) and shorter ACT (58 versus 65 versus 70 ms, <i>p</i> = 0.04). 28280732 2017
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic
0.010 Biomarker disease BEFREE Interestingly, MAP17 was originally reported to interact with PDZK1; in turn, the PDZK1 gene is localized within the atopic dermatitis-linked region on human chromosome 1q21. 19601982 2010
CUI: C0013595
Disease: Eczema
Eczema
0.010 Biomarker disease BEFREE Interestingly, MAP17 was originally reported to interact with PDZK1; in turn, the PDZK1 gene is localized within the atopic dermatitis-linked region on human chromosome 1q21. 19601982 2010
CUI: C0024121
Disease: Lung Neoplasms
Lung Neoplasms
0.010 Biomarker group BEFREE Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy. 30119639 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.010 Biomarker disease BEFREE To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors. 25837675 2015
CUI: C0034885
Disease: Rectal Neoplasms
Rectal Neoplasms
0.010 Biomarker group BEFREE In the present manuscript, we examined the values of MAP17 and pH2AX as surrogate biomarkers of the response in rectal tumors. 30250642 2018
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder)
0.010 Biomarker disease BEFREE In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas. 30119639 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.010 Biomarker disease BEFREE Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer. 29616128 2018